Abstract:
:In patients with acute leukemia, measurements of minimal residual disease (MRD) provide unique information on response to treatment. The most useful currently available MRD assays are polymerase chain reaction amplification of fusion transcripts and rearranged antigen-receptor genes and flow cytometric detection of aberrant immunophenotypes. Many studies in children and adults with acute lymphoblastic leukemia and acute myeloid leukemia have demonstrated a strong association between the presence of MRD and risk of relapse. Therefore, the use of information on MRD to adjust the intensity of therapy holds great potential for improving long-term clinical outcome. This article discusses the methodologies available for productive MRD testing and the clinical significance of the results.
journal_name
Curr Hematol Malig Repjournal_title
Current hematologic malignancy reportsauthors
Campana Ddoi
10.1007/s11899-008-0022-xsubject
Has Abstractpub_date
2008-07-01 00:00:00pages
155-60issue
3eissn
1558-8211issn
1558-822Xjournal_volume
3pub_type
杂志文章abstract::Morphologic dysplasia is an important factor in diagnosis of myelodysplastic syndrome (MDS). However, the role of dysplasia is changing as new molecular genetic and genomic technologies take a more prominent place in diagnosis. This review discusses the role of morphology in the diagnosis of MDS and its interactions w...
journal_title:Current hematologic malignancy reports
pub_type: 杂志文章,评审
doi:10.1007/s11899-017-0405-y
更新日期:2017-10-01 00:00:00
abstract::Compared with acute lymphoblastic leukemia (ALL) in older children, ALL in infants has a dismal outcome because rearrangements of the mixed-lineage leukemia (MLL) gene occur in about 80% of these patients, leading to an aggressive type of leukemia. With most recent therapies, about 50% long-term event-free survival is...
journal_title:Current hematologic malignancy reports
pub_type: 杂志文章,评审
doi:10.1007/s11899-009-0023-4
更新日期:2009-07-01 00:00:00
abstract::The diagnosis of lymphoma in pregnant patients poses a therapeutic challenge necessitating consideration of the developing fetus without compromise of therapy with curative potential for the mother. The decision to initiate therapy during pregnancy is heavily influenced by fetal, maternal, and disease-related factors,...
journal_title:Current hematologic malignancy reports
pub_type: 杂志文章,评审
doi:10.1007/s11899-017-0386-x
更新日期:2017-06-01 00:00:00
abstract:PURPOSE OF REVIEW:Ruxolitinib is the first FDA-approved JAK inhibitor for the treatment of myeloproliferative neoplasms and is an effective means of controlling symptom burden and improving splenomegaly. However, a majority of patients will develop disease progression with long-term use. Fedratinib, momelotinib, and pa...
journal_title:Current hematologic malignancy reports
pub_type: 杂志文章,评审
doi:10.1007/s11899-020-00596-z
更新日期:2020-12-01 00:00:00
abstract::The clonal blood disorders polycythemia vera, essential thrombocythemia and primary myelofibrosis belong to the BCR-ABL1-negative myeloproliferative neoplasms and are specified by increased production of terminally differentiated myeloid cells. Clonal evolution, disease initiation and progression are influenced by gen...
journal_title:Current hematologic malignancy reports
pub_type: 杂志文章,评审
doi:10.1007/s11899-013-0184-z
更新日期:2013-12-01 00:00:00
abstract::Progress in the understanding of the biology of chronic lymphocytic leukemia and in the development of new and effective therapies has generated a shift in treatment paradigms within only a few years. Traditional chemotherapy agents such as alkylators or nucleoside analogs are rapidly being replaced by combination reg...
journal_title:Current hematologic malignancy reports
pub_type: 杂志文章,评审
doi:10.1007/s11899-006-0006-7
更新日期:2006-12-01 00:00:00
abstract::Chronic myeloid leukemia (CML) arises as a consequence of a chromosomal translocation giving rise to the Philadelphia chromosome and Bcr-Abl oncogene. CML is a clonal disease of stem cell origin and an excellent example of a malignancy in which tumor-initiating cells may hold the key to disease eradication. The known ...
journal_title:Current hematologic malignancy reports
pub_type: 杂志文章,评审
doi:10.1007/s11899-010-0043-0
更新日期:2010-04-01 00:00:00
abstract:PURPOSE OF REVIEW:There are limited treatment options for relapsed/refractory classical Hodgkin lymphoma (cHL) patients who progress on brentuximab vedotin and programmed death-1 inhibitors. Camidanlumab Tesirine (Cami) is a new agent that has shown activity in multiply relapsed/refractory cHL patients. In this review,...
journal_title:Current hematologic malignancy reports
pub_type: 杂志文章,评审
doi:10.1007/s11899-021-00604-w
更新日期:2021-01-25 00:00:00
abstract::Multiple myeloma is a disorder of terminally differentiated plasma cells, characterized by immune dysfunction, deregulated signaling within the bone marrow stromal compartment, and a microenvironment that fosters immunosuppression. Immunomodulatory techniques, such as allogeneic hematopoietic stem cell transplant (all...
journal_title:Current hematologic malignancy reports
pub_type: 杂志文章,评审
doi:10.1007/s11899-015-0283-0
更新日期:2015-12-01 00:00:00
abstract:PURPOSE OF REVIEW:The use of circulating tumor DNA (ctDNA) for the purposes of diagnosis, prognosis, assessment of treatment response, and monitoring for relapse is a new and developing field in lymphoma. This review aims to summarize many of the most recent advances in ctDNA applications. RECENT FINDINGS:Recent studi...
journal_title:Current hematologic malignancy reports
pub_type: 杂志文章,评审
doi:10.1007/s11899-018-0468-4
更新日期:2018-10-01 00:00:00
abstract::Primary mediastinal B-cell lymphoma (PMBCL) is a relatively rare lymphoma subtype affecting mainly young adults. Its molecular signature and clinical features resemble classical Hodgkin lymphoma. The optimal chemotherapy for this lymphoma subtype has not been established. The addition of rituximab to anthracycline bas...
journal_title:Current hematologic malignancy reports
pub_type: 杂志文章
doi:10.1007/s11899-014-0219-0
更新日期:2014-09-01 00:00:00
abstract::Cutaneous T-cell lymphoma (CTCL) is a malignancy derived from a clonal population of mature, skin-homing lymphocytes. In the skin, the CTCL cells are associated with the Langerhans cells and respond to protumor cytokines. In turn, they upregulate T-cell receptor-dependent signaling pathways and subsequently demonstrat...
journal_title:Current hematologic malignancy reports
pub_type: 杂志文章,评审
doi:10.1007/s11899-007-0037-8
更新日期:2007-10-01 00:00:00
abstract::Allogeneic haematopoietic cell transplantation continues to be an important curative therapy for acute lymphoblastic leukaemia (ALL). Traditionally accepted indications for allografting adult ALL patients need reevaluation in light of outcomes with paediatric-like intensive regimens. Minimal residual disease status an...
journal_title:Current hematologic malignancy reports
pub_type: 杂志文章,评审
doi:10.1007/s11899-017-0371-4
更新日期:2017-04-01 00:00:00
abstract:PURPOSE OF REVIEW:Social media has dramatically changed the access and exchange of information in healthcare and beyond. A variety of platforms and resources exist allowing blood and marrow transplant providers, researchers, and patients to interact. We review the adoption of social media by the transplantation communi...
journal_title:Current hematologic malignancy reports
pub_type: 杂志文章,评审
doi:10.1007/s11899-018-0487-1
更新日期:2018-12-01 00:00:00
abstract::Most non-Hodgkin lymphomas (NHL) are of B-cell origin; only about 10% are T-cell or NK-cell lymphomas. The clinical features of T/NK-cell lymphomas differ from those of B-cell lymphomas: advanced stage and extranodal disease are more common and the prognosis is worse. Several studies have confirmed that 2-[fluorine-18...
journal_title:Current hematologic malignancy reports
pub_type: 杂志文章
doi:10.1007/s11899-011-0098-6
更新日期:2011-12-01 00:00:00
abstract:PURPOSE OF REVIEW:Determine if therapy of chronic myeloid leukaemia (CML) is a model for treating other cancers. RECENT FINDINGS:CML has a relatively homogeneous phenotype and genotype and is caused by one mutation, BCRABL1, in every instance. In contrast, most other leukaemias, haematologic cancers and solid cancer h...
journal_title:Current hematologic malignancy reports
pub_type: 杂志文章,评审
doi:10.1007/s11899-019-00555-3
更新日期:2019-12-01 00:00:00
abstract::Chronic myelomonocytic leukemia is a clonal malignancy of the ageing hematopoietic stem cell characterized by a biased differentiation leading to persistent monocytosis and inconstant hypersensitivity of myeloid progenitors to granulo-monocyte colony-stimulating factor (GM-CSF). Cytogenetic abnormalities identified in...
journal_title:Current hematologic malignancy reports
pub_type: 杂志文章,评审
doi:10.1007/s11899-014-0225-2
更新日期:2014-12-01 00:00:00
abstract::The advent of social media has led to the ability for individuals all over the world to communicate with each other, in real time, about mutual topics of interest in an unprecedented manner. Recently, the use of social media has increased among people interested in healthcare and medical research, particularly in the ...
journal_title:Current hematologic malignancy reports
pub_type: 杂志文章,评审
doi:10.1007/s11899-015-0287-9
更新日期:2015-12-01 00:00:00
abstract:PURPOSE OF REVIEW:Passive immunotherapy with therapeutic monoclonal antibodies (mAbs) has revolutionized the treatment of cancer, especially hematological malignancies over the last 20 years. While use of mAbs has improved outcomes, development of resistance is inevitable in most cases, hindering the long-term survival...
journal_title:Current hematologic malignancy reports
pub_type: 杂志文章,评审
doi:10.1007/s11899-019-00542-8
更新日期:2019-10-01 00:00:00
abstract::Patients with hematologic malignancies are increasing being prescribed oral anticancer medications (OAMs) and/or biologics. These newer targeted OAMs are associated with a host of practical and pharmacoeconomic implications for patients and healthcare providers. Issues such as safety, procurement challenges, and the n...
journal_title:Current hematologic malignancy reports
pub_type: 杂志文章,评审
doi:10.1007/s11899-016-0325-2
更新日期:2016-08-01 00:00:00
abstract::BCR-ABL-negative myeloproliferative neoplasms include primary myelofibrosis, polycythemia vera, and essential thrombocythemia. Clonal stem cell proliferation and dysregulated JAK/STAT molecular pathways characterize these hematologic malignancies. Symptoms experienced by patients are heterogeneous including excessive ...
journal_title:Current hematologic malignancy reports
pub_type: 杂志文章,评审
doi:10.1007/s11899-014-0239-9
更新日期:2014-12-01 00:00:00
abstract:PURPOSE OF REVIEW:The Choosing Wisely® initiative, led by the American Board of Internal Medicine Foundation in collaboration with national professional medical societies, aims to help patients choose care that is essential, free from harm, and evidence-based. The American Society of Hematology has advocated practices ...
journal_title:Current hematologic malignancy reports
pub_type: 杂志文章,评审
doi:10.1007/s11899-020-00593-2
更新日期:2020-08-01 00:00:00
abstract::Hodgkin lymphoma (HL) is a rare malignancy of the lymphatic system that is curable in at least 80 % of patients. Although patients usually present with painless lymphadenopathy, a variety of systemic and organ-specific syndromes may also exist in relation to HL. These syndromes may develop before, during, or after the...
journal_title:Current hematologic malignancy reports
pub_type: 杂志文章,评审
doi:10.1007/s11899-012-0131-4
更新日期:2012-09-01 00:00:00
abstract:PURPOSE OF REVIEW:CMV DNA polymerase inhibitors such as ganciclovir and foscarnet have dramatically reduced the burden of CMV infection in the HCT recipient. However, their use is often limited by toxicities and resistance. Agents with novel mechanisms and favorable toxicity profiles are critically needed. We review re...
journal_title:Current hematologic malignancy reports
pub_type: 杂志文章,评审
doi:10.1007/s11899-020-00557-6
更新日期:2020-04-01 00:00:00
abstract::Although the majority of patients with acute myeloid leukemia (AML) achieve a complete remission with induction chemotherapy, most will ultimately relapse. Therefore, the optimal postremission therapy for AML remains to be defined, and further improvements in treatment strategies are required. Clinical trials have dem...
journal_title:Current hematologic malignancy reports
pub_type: 杂志文章,评审
doi:10.1007/s11899-006-0021-8
更新日期:2006-06-01 00:00:00
abstract::The original version of this article unfortunately contained a mistake. The conflict of interest statement was incorrect. The corrected statement is given below. ...
journal_title:Current hematologic malignancy reports
pub_type: 已发布勘误
doi:10.1007/s11899-018-0488-0
更新日期:2019-02-01 00:00:00
abstract::The introduction of imatinib represented a breakthrough in the treatment of chronic myelogenous leukemia (CML). However, about 20% of patients treated in early chronic-phase CML are off therapy after 6 years because of resistance or intolerance, and most patients taking imatinib remain BCR-ABL-positive at the molecula...
journal_title:Current hematologic malignancy reports
pub_type: 杂志文章
doi:10.1007/s11899-008-0012-z
更新日期:2008-04-01 00:00:00
abstract::Haploidentical hematopoietic stem cell transplantation (HSCT) using mismatched family member donors has historically been complicated by high rates of nonrelapse toxicity and the need for laboratory expertise in depleting grafts of T lymphocytes. Over the past decade, improvements in supportive care, the increased use...
journal_title:Current hematologic malignancy reports
pub_type: 杂志文章,评审
doi:10.1007/s11899-007-0027-x
更新日期:2007-07-01 00:00:00
abstract::Just as a pawnshop owner who is unable to distinguish a genuine Rolex™ watch from a cheap knockoff courts financial ruin, the physician who fails to discriminate between authentic myelodysplastic syndromes (MDS) and conditions resembling MDS risks misinforming or harming patients. This review summarizes minimal criter...
journal_title:Current hematologic malignancy reports
pub_type: 杂志文章,评审
doi:10.1007/s11899-012-0140-3
更新日期:2012-12-01 00:00:00
abstract::Patients with acute leukemia who undergo hematopoietic stem cell transplantation (HSCT) are susceptible to malnutrition caused by several factors including intensive cytotoxic therapy. This paper discusses the significance of malnutrition in these patients and provides an overview of nutrition therapy by the oral, ent...
journal_title:Current hematologic malignancy reports
pub_type: 杂志文章,评审
doi:10.1007/s11899-996-0007-6
更新日期:2006-09-01 00:00:00